Marked Interindividual Variability in the Response to Selective Inhibitors of Cyclooxygenase-2
Susanne Fries, Tilo Großer, Thomas S. Price et al. · Gastroenterology · 2006
Cited by 139 works. doi:10.1053/j.gastro.2005.10.002 Open-access PDF
Authors
- Susanne Fries
- Tilo Großer
- Thomas S. Price
- John A. Lawson
- Shiv C. Kapoor
- Mathew T. Pletcher
- Tim Wiltshire
- Garret A. FitzGerald
References
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
- Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
- Selective Cumulative Inhibition of Platelet Thromboxane Production by Low-dose Aspirin in Healthy Subjects
- The Coxibs, Selective Inhibitors of Cyclooxygenase-2
- Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
- Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease.